Drug intelligence / Profile preview

CIL003

Development stage: Preclinical
Lead developer: Cilcare
Modality: Small Molecules

Overview

CIL003 is a novel small molecule drug candidate under preclinical development for the treatment of hearing disorders, with a particular focus on sensorineural hearing loss, hidden hearing loss (cochlear synaptopathy), and tinnitus. The compound is being developed by Cilcare, a biotech company specializing in auditory sciences, using proprietary AI-based algorithms to identify and advance therapies for auditory-related diseases. Shionogi holds an exclusive option to license global rights to develop, manufacture, and commercialize CIL003 based on ongoing preclinical results. While the precise mechanism of action has not been publicly disclosed as of June 2025, the drug is positioned as an innovative therapy targeting unmet needs in early-stage hearing impairment[1][2][3][4][6].

Other names: CIL 003CIL003CIL-003

Beyond the preview

Go deeper on CIL003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIL003.

Explore the full profile